OliPass Discloses Option Exercise Fee and Extends Contract with Vanda Pharma for Joint R&D on Rare Disease and Immuno-Oncology Drugs – Positive Collaboration Continuation
OliPass entered a joint R&D agreement with NASDAQ-listed Vanda Pharma for two drug candidates (rare disease and immuno-oncology), having already received the upfront payment of USD 3M (approx. KRW 4.3B).
The option exercise fee of USD 2M (approx. KRW 2.9B), previously confidential at Vanda's request, is now disclosed upon expiration of the confidentiality period.
The contract term has been extended to May 31, 2026, via Vanda's extension option, indicating continued partnership.
All R&D costs including personnel are borne by Vanda, posing no financial burden on OliPass.
[AI Summary]This disclosure reveals specific terms of the existing contract; while the option fee is modest, Vanda's ongoing investment commitment and potential future milestones/royalties positively impact shareholder value.
KOSDAQ Filing Information
Filing: [Correction of Description] Material Information for Investment Decision (Signing of Joint Research and Development Agreement with Vanda Pharmaceuticals for Development of Rare Disease Treatments and Immuno-Oncology Drugs Based on OliPass PNA Platform Technology)